

Ventech raises a new fund at €150 million

06/09/2007 - Press release

Ventech is pleased to announce the closing of its third Venture Capital Fund - VENTECH CAPITAL III - at €150m as targeted.

VENTECH CAPITAL III Fund, sponsored by Natixis Private Equity, attracted numerous new prestigious investors, such as AGF, CDC Entreprises, the Groupe Caisse d'Épargne or the Société Générale. Nearly half of the Fund has been raised with new investors, illustrating the credit given to Ventech team performance.

VENTECH CAPITAL III Fund already has 6 portfolio companies, among which Actogenix (Administration of therapeutic proteins and peptides), Crocus (Supplier of MRAM products and technologies), MXP4 (Digital Interactive Music Format), Skyrecon (Security Solutions Software) and Viadeo (Networking via Internet). The Fund will be invested in Ventech's focus area of early-stage Information Technology (Software, Hardware & Communications, and Applications & Services) and Biotechnology in Continental Europe.

With this third Fund, Ventech now has €325m under management, with VENTECH II (€112m) and VENTECH I (€62m). Investments in these funds include great successes, among which MeilleurTaux (IPOed as the first company on the Alternext Market at €150 million, with a 15x multiple) and Musiwave (sold to Openwave \$120 million, with a 10x multiple), two companies co-founded by Ventech. Alantos Pharmaceuticals, sold \$300 million to Amgen for a 5.5x multiple is another great recent example of success.

Since the creation of the first Fund, the team has achieved many other successes, with a global X 3 multiple on realized exits. Other successfully exited companies include Alapage.com, Altitude, Calendra, Evotec Neurosciences, Genesys, Internext, Kazibao, K-Mobile, Virtools and Sterilyo.

Global Private Equity was placement agent of VENTECH.